Evidence map›Paper›PMID 35681562›Full record

ArticleCancers2022

Searching for SARS-CoV-2 in Cancer Tissues: Results of an Extensive Methodologic Approach based on ACE2 and Furin Expression.

Sara Ricardo, Pedro Canão, Diana Martins, Ana C Magalhães, Marina Pereira, Ulysses Ribeiro-Junior, Evandro Sobroza de Mello, Venâncio A Alves, Regina Pinto, Dina Leitão and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Sara Ricardoi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0003-4091-2226
Pedro CanãoDepartment of Pathology, Centro Hospitalar e Universitário de São João, 4200-319 Porto, Portugal.
Diana MartinsDepartment of Pathology, Centro Hospitalar e Universitário de São João, 4200-319 Porto, Portugal.
Ana C Magalhãesi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-3988-3280
Marina PereiraInstituto do Câncer, Hospital de Clínicas (HCFMUSP), Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246000, Brazil.ORCID 0000-0002-6865-0988
Ulysses Ribeiro-JuniorInstituto do Câncer, Hospital de Clínicas (HCFMUSP), Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246000, Brazil.
Evandro Sobroza de MelloInstituto do Câncer, Hospital de Clínicas (HCFMUSP), Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246000, Brazil.
Venâncio A AlvesInstituto do Câncer, Hospital de Clínicas (HCFMUSP), Faculdade de Medicina, Universidade de São Paulo, São Paulo 01246000, Brazil.
Regina PintoIpatimup-Institute of Molecular Pathology and Immunology, University of Porto, 4200-465 Porto, Portugal.
Dina LeitãoMedical Faculty, University of Porto, 4200-319 Porto, Portugal.
Georgina Alvesi3S Diagnostics-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-3487-6321
Rute Oliveirai3S Diagnostics-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-4006-5103
Joana Wiltoni3S Diagnostics-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-3728-1833
Susete Costelhai3S Diagnostics-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.
Diana Meirelesi3S Diagnostics-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0003-4618-9112
Didier Cabanesi3S Diagnostics-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-4001-1332
Leonor Davidi3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, 4200-135 Porto, Portugal.ORCID 0000-0003-4207-9258
Fernando SchmittMedical Faculty, University of Porto, 4200-319 Porto, Portugal.ORCID 0000-0003-1006-6946
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTUniversidade do Porto · PTHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRHospital de São João · PT

Funding

Fundação para a Ciência e Tecnologia Proj 510
6 · The paper itself

Abstract

SARS-CoV-2 pandemics have been massively characterized on a global scale by the rapid generation of in-depth genomic information. The main entry gate of SARS-CoV-2 in human cells is the angiotensin-converting enzyme 2 (ACE2) receptor. The expression of this protein has been reported in several human tissues, suggesting a correlation between SARS-CoV-2 organotropism and ACE2 distribution. In this study, we selected (a series of) 90 patients who were submitted to surgery for tumor removal between the beginning of the SARS-CoV-2 pandemic and the closure of operating rooms (by the end of March 2020) in two different countries-Portugal and Brazil. We evaluated the expressions of ACE2 and furin (another important factor for virus internalization) in colon (

Indexed as

ACE2cancer tissuesinfection tropismSARS-CoV-2

Identifiers

PMID35681562
PMCPMC9179515
OpenAlexW4281569547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.